BioCentury
ARTICLE | Clinical News

Molecular Templates reports Phase I data for NHL candidate

June 1, 2018 5:49 PM UTC

Molecular Templates Inc. (NASDAQ:MTEM) reported interim data from 24 evaluable patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) in a Phase I trial showing that MT-3724 led to an overall response rate (ORR) of 12.5%, including one complete response and two partial responses, plus two cases of stable disease. The data were released in an abstract ahead of the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The open-label, dose-escalation, U.S. trial is enrolling about 60 patients with B cell non-Hodgkin's lymphoma (NHL) who previously relapsed after a prior response to an anti-CD20 mAb and chemotherapy to receive IV MT-3724 for up to five cycles each comprising six infusions over 12 days...